Seurat Therapeutics, founded at the University of Chicago and headquartered in Chicago, Illinois, is a privately held biopharmaceutical company. Their core mission is to transform neurological research breakthroughs into novel medications to treat debilitating nervous system disorders, including migraine headaches, fibromyalgia, chronic pain syndromes, and epileptic seizure disorders. The company leverages years of research from the University of Chicago medical center to innovate migraine care and accelerate the translation of scientific discoveries into life-changing medicine.

Notable affiliated individuals include researchers and scientists from the University of Chicago who have contributed to the foundational research behind Seurat Therapeutics. The company operates out of the Polsky Exchange, a hub for innovation and entrepreneurship. Key achievements include advancing the understanding of neurological disorders and developing potential therapeutic solutions. Seurat Therapeutics has made a significant impact by focusing on conditions that severely affect quality of life, aiming to provide effective treatments where current options are limited.